urogenital tumors |
Phase II study of sunitinib in men with advanced prostate cancer
1 Division of Hematology/Oncology, Massachusetts General Hospital
2 Department of Medical Oncology, Dana Farber Cancer Institute
3 Department of Medicine, Harvard Medical School
4 Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute, Boston, USA
* Correspondence to: Dr M. Dror Michaelson, Massachusetts General Hospital Cancer Center, 55 Fruit Street, Yawkey 7E, Boston, MA 02114, USA. Tel: +1-617-726-1594; Fax: +1-617-726-3440; E-mail: dmichaelson1{at}partners.org
Background: This study explored the efficacy and tolerability of sunitinib, an inhibitor of tyrosine kinase receptors, in men with castration-resistant prostate cancer (CRPC).
Methods: Men with no prior chemotherapy (group A) and men with docetaxel (Taxotere)-resistant prostate cancer (group B) were treated with sunitinib. The primary end point was confirmed 50% prostate-specific antigen (PSA) decline. Secondary end points included objective response rate and safety. Serum-soluble biomarkers were measured.
Results: Seventeen men were enrolled in each group. One confirmed PSA response was observed in each group, and an additional eight men and seven men had stable PSA at week 12 in groups A and B, respectively. Improvements in imaging were observed in the absence of post-treatment PSA declines. Common adverse effects included fatigue, nausea, diarrhea, myelosuppression and transaminase elevation. Significant changes following sunitinib treatment were observed in serum-soluble biomarkers including soluble vascular endothelial growth factor receptor-2, platelet-derived growth factor aa, placental growth factor and leptin.
Conclusions: Sunitinib monotherapy resulted in few confirmed 50% post-treatment declines in PSA in men with CRPC. Serum markers of angiogenesis confirmed on-target effects of sunitinib. Assessments of radiographic disease status were often discordant with changes in PSA, indicating that alternate end points are important in future trials.
Key words: angiogenesis, castration, docetaxel, PSA, resistant
Received for publication January 7, 2009. Revision received February 25, 2009. Accepted for publication March 4, 2009.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. B. Aragon-Ching and W. L. Dahut About tyrosine kinase inhibitors (TKIs) in prostate cancer: where do we go from here? Ann. Onc., November 10, 2009; (2009) mdp467v1. [Full Text] [PDF]
|
|
|
|
 |
|
 I. C. Song, J. S. Lim, H. J. Yun, S. Kim, D. Y. Kang, and H. J. Lee Biochemical and Pathological Response of Prostate Cancer in a Patient with Metastatic Renal Cell Carcinoma on Sunitinib Treatment Jpn. J. Clin. Oncol., September 22, 2009; (2009) hyp110v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Sonpavde, P. O. Periman, D. Bernold, D. Weckstein, M. T. Fleming, M. D. Galsky, W. R. Berry, F. Zhan, K. A. Boehm, L. Asmar, et al. Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy Ann. Onc., July 24, 2009; (2009) mdp323v1. [Abstract] [Full Text] [PDF]
|
|